Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04078191 · ClinicalTrials.gov registry record · Phase 2
Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA
A Phase 2 study, sponsored by Navidea Biopharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT04078191 is a Phase 2 study that was terminated before completion, run by Navidea Biopharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT04078191, a Phase 2 study, was terminated before completion, sponsored by Navidea Biopharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is a comparison of quantitative Tc 99m tilmanocept imaging with IHC analysis of CD206 expression in synovial tissue of RA subjects.
Interventions
- DRUG Tc 99m tilmanocept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-09-14 |
| Est. Completion | 2024-07-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04078191
The ClinicalTrials.gov registry entry for NCT04078191 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Navidea Biopharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tc 99m tilmanocept is the first listed.
NCT04078191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04078191 about?
NCT04078191 is a clinical study titled "Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA". This study is a comparison of quantitative Tc 99m tilmanocept imaging with IHC analysis of CD206 expression in synovial tissue of RA subjects.
What is the current status of trial NCT04078191?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2021-09-14. Estimated completion is 2024-07-09.
What interventions are being tested in trial NCT04078191?
The interventions under investigation include: Tc 99m tilmanocept (DRUG).
Who is sponsoring clinical trial NCT04078191?
This trial is sponsored by Navidea Biopharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.